Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

an anemia blood disorder. With these results, we expect an FDA filing for the drug in the back half of this year for approval. The company also sold its 15% royalty on a cancer drug, which ...

Zydus will set its own prices for the generic product, paying a royalty on sales to Gilead to ... inhibitor (HIF-PHI), as a treatment for anemia associated with Chronic Kidney Disease (CKD).

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

Tivic Health Systems, Inc., today announced it has acquired worldwide exclusive license rights from Statera Biopharma to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimodtm for the ...

It’s a jungle out there. Deriving the right royalty rate for new pharmaceuticals and biotechnologies is a real tangle. This is a critical business function, and it has never been more important ...

HELLO! brings you the latest news, photos and exclusives from the British Royal Family as they happen. The British royals are well-known for their charity work and public support of numerous ...

Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...

Speaking anonymously to Yes, Ma'am - The Secret Life of Royal Servants by Tom Quinn, a new book which will be out this month, an insider offered insight into the former actress' plans for ...